Literature DB >> 6107947

Neuroleptic blood levels and therapeutic effect.

B M Cohen, J F Lipinski, H G Pope, P Q Harris, R I Altesman.   

Abstract

Studies attempting to delineate a therapeutic range of blood levels for neuroleptics have yielded conflicting results. The reasons for this are briefly reviewed and a study is described in which a correlation is sought between blood levels of thioridazine and clinical efficacy. The study employs the radioreceptor assay for neuroleptics to detect both parent drug and active metabolites in blood. The results of the study indicate that while dose is a poor predictor of blood levels of medication, blood levels of neuroleptic activity in patients on thioridazine may be very highly correlated with antipsychotic effect.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6107947     DOI: 10.1007/bf00435313

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  9 in total

1.  Thymoleptic and neuroleptic drug plasma levels in psychiatry: current status.

Authors:  T B Cooper; G M Simpson; J H Lee
Journal:  Int Rev Neurobiol       Date:  1976       Impact factor: 3.230

2.  A simple and sensitive radioreceptor assay for antischizophrenic drugs in blood.

Authors:  I Creese; S H Snyder
Journal:  Nature       Date:  1977-11-10       Impact factor: 49.962

3.  Clinical use of the radioreceptor assay for neuroleptics.

Authors:  B M Cohen; J F Lipinski; P Q Harris; H G Pope; M Friedman
Journal:  Psychiatry Res       Date:  1980-05       Impact factor: 3.222

4.  Radioreceptor assay of haloperidol tissue levels in the rat.

Authors:  B M Cohen; M Herschel; E Miller; H Mayberg; R J Baldessarini
Journal:  Neuropharmacology       Date:  1980-07       Impact factor: 5.250

5.  Diagnostic criteria for use in psychiatric research.

Authors:  J P Feighner; E Robins; S B Guze; R A Woodruff; G Winokur; R Munoz
Journal:  Arch Gen Psychiatry       Date:  1972-01

6.  Neuroleptic drug levels and therapeutic response: preliminary observations with red blood cell bound butaperazine.

Authors:  D L Garver; H Dekirmenjian; J M Davis; R Casper; S Ericksen
Journal:  Am J Psychiatry       Date:  1977-03       Impact factor: 18.112

Review 7.  Monitoring plasma concentrations of neuroleptics.

Authors:  M Lader
Journal:  Pharmakopsychiatr Neuropsychopharmakol       Date:  1976-07

8.  Neuroleptic, antimuscarinic, and antiadrenergic activity of chlorpromazine, thioridazine, and their metabolites.

Authors:  B M Cohen; M Herschel; A Aoba
Journal:  Psychiatry Res       Date:  1979-10       Impact factor: 3.222

9.  Plasma levels of chlorpromazine in schizophrenia; a critical review of the literature.

Authors:  P R May; T Van Putten
Journal:  Arch Gen Psychiatry       Date:  1978-09
  9 in total
  5 in total

1.  Serum neuroleptic concentrations and clinical response: a radioreceptor assay investigation of acutely psychotic patients.

Authors:  L T Kucharski; P Alexander; L Tune; J Coyle
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

Review 2.  The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia.

Authors:  S Ulrich; C Wurthmann; M Brosz; F P Meyer
Journal:  Clin Pharmacokinet       Date:  1998-03       Impact factor: 6.447

Review 3.  Plasma level monitoring of antipsychotic drugs. Clinical utility.

Authors:  S G Dahl
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

4.  Dopamine, serotonin and alpha-adrenergic receptor blocking activities in serum and their relationships to prolactin level in schizophrenic patients receiving long-term chlorpromazine treatment.

Authors:  T Nakahara; M Hirano; H Uchimura; M Saito; J S Kim; T Matsumoto; H Yokoo; M Shimomura; A Mukai
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

5.  A fixed dose study of the plasma concentration and clinical effects of thioridazine and its major metabolites.

Authors:  B M Cohen; J F Lipinski; C Waternaux
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.